Efficacy for a New Live Attenuated Salmonella Enteritidis Vaccine Candidate to Reduce Internal Egg Contamination

To evaluate the efficacy of a novel attenuated Salmonella Enteritidis (△lon△cpxR) vaccine candidate (JOL919), chickens were immunized through oral and intramuscular routes to reduce egg contamination against S. Enteritidis challenge. Birds were orally immunized with JOL919 on the first day of life and were subsequently boosted in the 6th and 16th weeks through oral (group B) or intramuscular (group C) route, while control birds were unimmunized (group A). The chickens of all groups were challenged intravenously with the virulent S. Enteritidis strain in the 24th week. The immunized groups B and C showed significantly higher plasma IgG and intestinal secretory IgA levels as compared to those of the control group. The lymphocyte proliferation response and CD45⁺CD3⁺ T‐cell number in the peripheral blood of the groups B and C were significantly increased. In addition, the egg contamination rates were significantly lower in the group B (0%, 10.7% and 0%) and the group C (3.6%, 14.3% and 3.6%) as compared to the group A (28.6%, 42.8% and 28.6%) in the 1st, 2nd and 3rd weeks post‐challenge. All animals in the groups B and C showed lower organ lesion scores in the liver and spleen and lower bacterial counts in the liver, spleen and ovary at the 3rd week post‐challenge. These results indicate that this vaccine candidate can be an efficient tool for prevention of Salmonella infections by inducing protective humoral and cellular immune responses. In addition, this vaccine did not prevent egg contamination, but did appear to reduce incidence. Booster immunizations, especially via oral administration route, showed an efficient protection against internal egg contamination with S. Enteritidis.     

甲鱼嗜水气单胞菌病灭活菌苗的研究

利用嗜水气单胞菌研制了甲鱼嗜水气单胞菌病灭活菌苗,每只甲鱼肌肉注射1.0毫升,14天后产生免疫力,40MLD攻毒100%(15/15)得到保护,免疫期达9个月,4℃保存至少3个月效力不减。现场应用保护率达98%(98/100),无任何副作用及不良反应。     

Protection of Procambarus clarkii against white spot syndrome virus using recombinant subunit injection vaccine expressed in Pichia pastoris

ABSTRACT:   The potentiality of injection vaccine against white spot syndrome virus (WSSV) in crayfish Procambarus clarkii was investigated. WSSV envelope proteins VP19 and VP28 were expressed in yeast Pichia pastoris GS115. The purified recombinant proteins (2 µg/g of crayfish) were injected intramuscularly, and the same dose injected as a booster shot on fifth day after vaccination. The vaccinated crayfish were divided into two even groups and later challenged orally by WSSV-infected dead crayfish muscle (2 g/individual) on the third and 21st days after the booster shot. The relative percent survival (RPS) in the third-day group was the highest in VP28 (91%), followed by VP19 + VP28 (84%), and VP19 (45%). The RPS for the 21st-day group was the highest in VP28 (78%), followed by VP19 + VP28 (76%), and VP19 (17%). Development of vaccine by using recombinant proteins VP19 and VP28 expressed in yeast is feasible.     

草鱼出血病细胞培养灭活疫苗的研究——疫苗株的免疫原性及其有效免疫剂量的比较

本文比较了疫苗株FR—854和FR—836—w的免疫原性,及其对三寸左右草鱼种的有效免疫剂量。疫苗株FR—854和FR—836—w均有较强的免疫原性,其保护力可达70％以上。但试验结果初步证明,FR—854疫苗比FR—836—w疫苗免疫原性更强。经统计分析,FR—854疫苗的免疫保护力可达88.9±12.0(6)％,血清中和抗体效价为160.5±58.9(6);而FR-838-W疫苗分别只有71.3±14.2(6)％、88.3±26.2(6);二者有显著的差异(0.05>P>0.01)。注射免疫三寸左右的草鱼种,FR—854的免疫剂量在3—5×10~(4.5)TCID_(50)/尾左右,FR—836—w在3—5×10~(7.5)TCID_(50)/尾左右,其免疫保护力可达80％左右,同时我们测得ER—854的半数免疫量为10~(5.1)TCID_(50)/ml。     

DNA疫苗在动物疾病预防中的研究进展

DNA疫苗的出现是疫苗研究史上重大事件,被誉为疫苗研究的第三次革命。DNA疫苗既能激发机体的细胞免疫,也能诱导特异性的体液免疫,在预防和治疗细菌、病毒、寄生虫等感染性疾病等方面具有广阔的应用前景。利用DNA疫苗预防动物疾病是DNA疫苗发展的一个重要方面,并且在一些重大动物疾病预防研究上取得许多突破。可以肯定,随着人们对DNA疫苗免疫机制深入理解以及提高其诱导特异性免疫应答水平经验的积累,DNA疫苗定会在预防动物各种疾病方面发挥巨大作用。     

高致病性猪蓝耳病弱毒疫苗与灭活苗免疫效果评估及综合防控措施

本试验研究通过相同饲养条件下的35日龄仔猪分别使用高致病性猪蓝耳病弱毒疫苗与灭活苗进行高致病性猪蓝耳病首免,并分别在首免当日、28日、58日检测高致病性猪蓝耳病免疫抗体水平,结果发现,使用弱毒疫苗免疫的猪高致病性蓝耳病抗体上升速度和抗体水平均优于使用灭活苗的猪。试验结果表明弱毒灭活苗可在接种后21-28日产生免疫力,免疫期为4个月,猪繁殖与呼吸综合征流行的地区应该首先考虑使用弱毒活疫苗。     

基于化学蚀变指数的湟水河流域化学风化分析

以青海省湟水河表层沉积物为研究对象,选取该河流沉积物常量元素含量、CIA风化程度指数,通过与大陆壳表层、黄土相关元素的对比,分析了湟水河流域地表化学风化程度.结果表明,湟水河沉积物富Ca、m,而K在全流域含量变化小,与大陆壳表层含量基本一致,表明湟水河流域地表物质化学风化程度低,处于饱和硅铝阶段早期（即脱Ca、Na阶段）,地表的物理风化强于化学风化;CIA值大致反映了化学风化的程度,在中游段CIA低,上游和下游段CIA较高,具有相对稍强的化学风化过程.     

鸡白细胞介素-18对H9亚型禽流感灭活油乳苗的免疫增强作用

[目的]探索鸡白细胞介素-18（IL-18）在H9禽流感（AI）灭活油乳苗免疫中的免疫佐剂作用.[方法]从鸡脾淋巴细胞中克隆鸡IL-18基因,亚克隆到真核表达载体pcDNA3.1（＋）中,构建真核表达质粒pIL-18.将重组真核表达质粒pIL-18、H9亚型AI灭活油乳苗及其二者联合分别免疫14日龄SPF鸡,检测其细胞免疫和体液免疫水平,评价鸡IL-18在H9亚型禽流感灭活油乳苗中的免疫增强作用.[结果]成功克隆了鸡IL-18全基因,大小为597 bp.质粒pIL-18和H9亚型AI灭活油乳苗联合免疫的SPF鸡所产生的HI抗体效价在接种第4周后明显高于H9亚型AI灭活油乳苗免疫组;其T淋巴细胞的增殖反应也强于H9亚型AI灭活油乳苗免疫组.[结论]质粒pIL-18能提高H9亚型禽流感灭活油乳苗诱发的免疫应答,为研究防制禽流感的新型疫苗提供了新思路.     

动物布鲁氏菌病疫苗的来历及亚单位疫苗的研究概况

布鲁氏菌病是一种严重危害人和动物健康的人畜共患病,人群感染主要来源于感染的动物及被污染的畜产品,目前疫苗免疫仍是控制动物布鲁氏菌病的主要措施。现有国际参考疫苗主要有牛种疫苗株S19和羊种疫苗株Rev.1,这些疫苗为动物群布鲁氏菌病控制提供重要保障的同时也存在关键的技术瓶颈问题,如安全性差,接种动物出现流产;血清抗体体内持续时间较长,干扰常规诊断等。随着布鲁氏菌基因组测序工作的相继完成及DNA重组技术的发展,新型布鲁氏菌病疫苗的开发成为研究的热点。亚单位疫苗本着其较高的安全性和有效性,在动物群布鲁氏菌病控制过程中具有较大的应用前景。笔者综述了布鲁氏菌病疫苗的发展史,并对布鲁氏菌病亚单位疫苗的研究进展进行概述。     

猪圆环病毒2 型疫苗研究进展

疫苗免疫接种是防控猪圆环病毒2型(Porcine circovirus type 2,PCV-2)的主要方式,PCV-2疫苗的研究与开发已成为国内外兽医工作者的关注热点.在国际市场上销售的商品化PCV-2疫苗主要包括亚单位疫苗、嵌合病毒疫苗和灭活疫苗,其中PCV-2灭活疫苗已在我国规模化猪场中广泛使用.综述了近年来国内外各类PCV-2疫苗研究进展及存在的问题,以期为猪圆环病毒病的防制与PCV-2新型疫苗的研发提供参考.